Search
Ganaxolone
go.drugbank.com/drugs/DB05087ApprovedInvestigational[L41135] In July 2023, ganaxolone was also approved under the same brand name and for the same indication by the EMA.[L47636] … [L41130] It was approved under the brand name ZTALMY by the US FDA in March 2022 for the treatment of seizures associated with CDKL5 deficiency disorder (CDD), becoming the first FDA-approved treatment
Acalabrutinib
go.drugbank.com/drugs/DB11703ApprovedInvestigationalTo date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. … [L42795,L42800] Unlike Calquence capsules, the co-administration of Calquence tablets and PPIs does not have an effect in the pharmacokinetics of acalabrutinib.
Diethylamino hydroxybenzoyl hexyl benzoate
go.drugbank.com/drugs/DB11269ApprovedIt is used in concentrations up to 10% in sunscreen products, either alone or in combination with other UV absorbers [F107]. … Diethylamino hydroxybenzoyl hexyl benzoate was approved in Europe in 2005, and is also marketed in the U.S., South America, Mexico, Japan and Taiwan.
Mixtures: The History of Whoo Jin Hae Yoon Sun, Kiehls Activated Sun Protector Sunscreen SPF 50 For Face and Body For All Skin TypesEfgartigimod alfa
go.drugbank.com/drugs/DB15270ApprovedInvestigational[A243759,A243784] Efgartigimod alfa is a first-in-class[L39501] antagonist of the neonatal Fc receptor (FcRn) used in the treatment of MG. … and a reduction in electrical nerve impulses.
Delgocitinib
go.drugbank.com/drugs/DB16133ApprovedInvestigationalDelgocitinib is a pan-Janus kinase (JAK) inhibitor. After the first global approval in Japan,[A264693] delgocitinib was also approved by the European Commission on September 23, 2024. … [L51913] It works to reduce the inflammatory response in inflammatory skin disorders.[A264703] On July 23, 2025, delgocitinib was also granted approval by the FDA.[L53508]
L-Acetylleucine
go.drugbank.com/drugs/DB16956ApprovedInvestigationalLevacetylleucine (L-acetylleucine) is a modified acetylated derivative of the amino acid [leucine]. The racemic (i.e. DL-) form has been available in France since 1957 for the treatment of vertigo. … [A264439] In September 2024, the FDA approved levacetylleucine for the treatment of select patients with NPC.[L51444]
Synonyms: N-acetyl leucine, N-acetylleucineIptacopan
go.drugbank.com/drugs/DB16200ApprovedInvestigational[A262581] This is of particular importance to PNH, where one of the disease hallmarks is the mutation of the PIGA gene. … [A262566] Factor B is a positive regulator of the alternative complement pathway, where it activates C3 convertase and subsequently C5 convertase.
Categories: Compounds used in a research, industrial, or household settingBordetella pertussis fimbriae 2/3 antigen
go.drugbank.com/drugs/DB10790ApprovedInvestigationalBordetella pertussis fimbriae 2/3 antigen is a vaccine for the prophylaxis of the disease caused by Bordetella pertussis which is a a Gram-negative coccobacillus that expresses two serologically distinct
Mixtures: Repevax Injektionssuspension in einer Fertigspritze, Covaxis Injektionssuspension in einer FertigspritzeNitazoxanide
go.drugbank.com/drugs/DB00507ApprovedInvestigationalVet approvedNitazoxanide is a first-line, standard treatment for illness caused by C. parvum or G. lamblia infection in healthy (not immunosuppressed) adults and children and may also be considered in the treatment … This drug is effective in the treatment of gastrointestinal infections including Cryptosporidium parvum or Giardia lamblia in healthy subjects. It is generally well tolerated.
Products: N/aPropiverine
go.drugbank.com/drugs/DB12278ApprovedOveractive bladder syndrome affects millions of elderly individuals in the United States and shows equal prevalence in men and women. … Propiverine is a widely used antimuscarinic drug with a mixed mode of action in the treatment of symptoms associated with overactive bladder (OAB) [A32576].